EP0686047B1 - Ligands de 5-ht 1a - Google Patents
Ligands de 5-ht 1a Download PDFInfo
- Publication number
- EP0686047B1 EP0686047B1 EP94906348A EP94906348A EP0686047B1 EP 0686047 B1 EP0686047 B1 EP 0686047B1 EP 94906348 A EP94906348 A EP 94906348A EP 94906348 A EP94906348 A EP 94906348A EP 0686047 B1 EP0686047 B1 EP 0686047B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- procedure
- selective
- compound
- radiolabelled
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003446 ligand Substances 0.000 title abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 25
- 238000002600 positron emission tomography Methods 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 22
- 239000002287 radioligand Substances 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 239000003727 serotonin 1A antagonist Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 abstract description 18
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 238000012216 screening Methods 0.000 abstract description 2
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 abstract 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 abstract 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- 239000000556 agonist Substances 0.000 description 7
- ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000003518 presynaptic effect Effects 0.000 description 5
- INQOMBQAUSQDDS-BJUDXGSMSA-N iodomethane Chemical compound I[11CH3] INQOMBQAUSQDDS-BJUDXGSMSA-N 0.000 description 4
- 230000001242 postsynaptic effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000004031 partial agonist Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004659 Presynaptic Receptors Human genes 0.000 description 2
- 108010003717 Presynaptic Receptors Proteins 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010304 firing Methods 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- XIGAHNVCEFUYOV-BTJKTKAUSA-N (z)-but-2-enedioic acid;n-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-n-pyridin-2-ylcyclohexanecarboxamide Chemical compound OC(=O)\C=C/C(O)=O.COC1=CC=CC=C1N1CCN(CCN(C(=O)C2CCCCC2)C=2N=CC=CC=2)CC1 XIGAHNVCEFUYOV-BTJKTKAUSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 241001263092 Alchornea latifolia Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000007527 Autoreceptors Human genes 0.000 description 1
- 108010071131 Autoreceptors Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000287181 Sturnus vulgaris Species 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- OKKJLVBELUTLKV-BJUDXGSMSA-N ac1l9oz4 Chemical compound O[11CH3] OKKJLVBELUTLKV-BJUDXGSMSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- RHJVIGLEIFVHIJ-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1[CH]CCCC1 RHJVIGLEIFVHIJ-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- CURLTUGMZLYLDI-BJUDXGSMSA-N methanedione Chemical compound O=[11C]=O CURLTUGMZLYLDI-BJUDXGSMSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000001690 micro-dialysis Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000008062 neuronal firing Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Definitions
- This invention relates to certain 5-HT 1A ligands which are radiolabelled with 11 C.
- 5-HT 1A ligands having specified characteristics can be labelled with with 11 C to give radiolabelled ligands making them particularly useful in, for example, pharmacological screening procedures or in positron emission tomography (PET) studies.
- the 5-HT 1A ligands that are suitable for such radiolabelling are selective 5-HT 1A antagonists.
- selective 5-HT 1A antagonists are meant compounds which:
- the compounds are tested for the 5-HT 1A binding properties by measuring their ability to displace [ 3 H]-8-OH-DPAT from the 5-HT 1A receptor in rat hippocampal membranes according to the procedure of B.S. Alexander and M.D. Wood, J. Pharm. Pharmacol., 1988 40 , 888-891.
- a compound is regarded as highly potent in this procedure if it has an IC 50 of 50nM or less.
- the affinity of the compounds for D 2 receptor sites is determined by the procedure of P. Seeman et al., J. Neurochem., 1984, 43 , 221-235.
- the affinity of the compound for ⁇ 1 sites is determined by the procedure of A.L. Morrow et al., Mol. Pharmacol., 1986, 29 , 321.
- the affinity of the compound for 5-HT 2A sites is determined by the procedure of R.A. Lyon et al., Mol. Pharmacol., 1987, 31 , 194-199. (The 5-HT 2A site was previously known as the 5-HT 2 site).
- a compound is regarded as being 25 fold selective if the IC 50 value for each of the D 2 , ⁇ 1 and 5-HT 2A sites as determined above is at least 25 times the IC 50 value for the 5-HT 1A site as determined in Procedure (A).
- the compound should be 50 fold selective.
- the compound is 25 fold selective (preferably 50 fold selective) over one or more of the 5-NT 1B , 5-HT 2C , 5-HT 1D , 5-HT 3 , ⁇ 2 , ⁇ and D 1 sites.
- the affinity for these sites is determined by the following procedures.
- This procedure determines whether a compound that has 5-HT 1A binding activity (as determined by procedure (A) possesses agonist and/or antagonist activity.
- Brain 5-HT 1A receptors exist as two populations in the brain i.e. postsynaptic 5-HT 1A receptors and presynaptic somatodendritic 5-HT 1A receptors.
- the presynaptic receptors are particularly sensitive to the agonist properties of 5-HT 1A receptor ligands and are activated by compounds designated 'partial agonists', which function as antagonists at the postsynaptic receptor.
- the present invention provides a selective 5-HT 1A -antagonist radio labelled with 11 C.
- the suitable 5-HT 1A -antagonists which may be radiolabelled are described, for example, in GB-A-2255337.
- the suitable compounds are
- the compound has an IC 50 value of 2.2nM according to procedure (A).
- procedure (B) the percentage inhibition of binding by the compound at 10 -6 M was ⁇ 50% at the following sites:- 5-HT 1B , 5-HT 2C , 5-HT 1D , 5-HT 2A , ⁇ 2 , ⁇ , D 1 , and D 2 (an inhibition of ⁇ 50% at 10 -6 M means that the binding affinity is very low). Its binding affinity at ⁇ 1 , sites was 230 nM.
- Selective 5-HT 1A antagonists radiolabelled with 11 C are useful as radioligands in Positron Emission Tomography (PET) studies. Such studies are carried out in vivo in animals and more preferably in humans.
- the 11 C serves as a positron source producing gamma rays. These rays are detected by the PET scanner and the resulting data is processed by computer so as to give information on the distribution of the radioligand in the living subject.
- PET Positron Emission Tomography
- the 11 C radiolabelled selective 5-HT 1A antagonist may be used in the PET studies as for example, a research tool or as a diagnostic aid.
- the potency and duration of an orally or parenterally administered unlabelled drug, which is a 5-HT 1A ligand can be measured by following the displacement of the 11 C labelled selective 5-HT 1A -antagonist from the brain of humans.
- PET studies using 11 C radiolabelled selective 5-HT 1A ligands can be used to study the distribution and nature of 5-HT 1A receptor sites as a function of disease states (e.g. Alzheimer's Disease or depression) and hence can be used to diagnose such disease stares.
- the 11 C radiolabelled selective 5-HT 1A antagonists may be prepared by methods known in the art.
- a precursor of the antagonist may be reacted with a 11 C containing reagent such that the radioisotope is incorporated into the resulting molecule of the antagonist.
- a phenol precursor of an antagonist may be alkylated with a radiolabelled alkylating agent, e.g. [ 11 C]methyl iodide to provide the antagonist containing a radiolabelled methoxy substituted phenyl group.
- the [ 11 C]methyl iodide may be produced via [ 11 C]methanol from cyclotron-produced [ 11 C]carbon dioxide.
- N-(2-(4-(2-hydroxyphenyl)-1-piperazinyl))ethyl)-N-(2-pyridyl)cyclohexane carboxamide may be alkylated with [ 11 C]-methyliodide to give 11 C labelled N-(2-(1-(4-(2-methoxyphenyl))-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (3)
- Antagoniste sélectif de 5-HT1A radiomarqué au 11C dans lequel l'antagoniste sélectif de 5-HT1A est le N-(2-(1-(4-(2-méthoxyphényl)-pipérazinyl))-éthyl)-N-(2-pyridinyl)cyclohexanecarboxamide ou un sel pharmaceutiquement acceptable de celui-ci.
- [Méthoxy-11C]N-(2-(1-(4-(2-méthoxyphényl)-pipérazinyl))-éthyl)-N-(2-pyridinyl)cyclohexane-carboxamide ou un sel pharmaceutiquement acceptable de celui-ci.
- Procédé d'utilisation d'un radioligand comme outil de recherche dans une étude de tomographie par émission de positrons caractérisé en ce que le radioligand est un composé selon la revendication 1 ou la revendication 2.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9303968 | 1993-02-26 | ||
GB939303968A GB9303968D0 (en) | 1993-02-26 | 1993-02-26 | 5-ht1a ligands |
PCT/GB1994/000324 WO1994019026A1 (fr) | 1993-02-26 | 1994-02-17 | Ligands de 5-ht¿1a? |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0686047A1 EP0686047A1 (fr) | 1995-12-13 |
EP0686047B1 true EP0686047B1 (fr) | 2000-01-12 |
Family
ID=10731124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP94906348A Expired - Lifetime EP0686047B1 (fr) | 1993-02-26 | 1994-02-17 | Ligands de 5-ht 1a |
Country Status (12)
Country | Link |
---|---|
US (1) | US6056942A (fr) |
EP (1) | EP0686047B1 (fr) |
AT (1) | ATE188614T1 (fr) |
AU (1) | AU6009694A (fr) |
DE (1) | DE69422611T2 (fr) |
DK (1) | DK0686047T3 (fr) |
ES (1) | ES2141819T3 (fr) |
GB (1) | GB9303968D0 (fr) |
GR (1) | GR3032479T3 (fr) |
MX (1) | MX9401415A (fr) |
PT (1) | PT686047E (fr) |
WO (1) | WO1994019026A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9413772D0 (en) * | 1994-07-08 | 1994-08-24 | Wyeth John & Brother Ltd | 5-HT1A ligands |
CA2396066A1 (fr) * | 2000-01-19 | 2001-07-26 | Akzo Nobel N.V. | Association de medicaments pour le traitement de depressions et de troubles s'y rapportant, comprenant de la mirtazapine |
DE60139032D1 (de) * | 2001-08-09 | 2009-07-30 | Miret Lab | Neue konservierungssysteme und deren verwendung in kosmetischen mitteln |
BRPI0114147B1 (pt) | 2001-08-09 | 2017-06-27 | Laboratorios Miret, S.A. | Cosmetic or dermatological composition in the form of an emulsion understanding cationic surfaces |
DK1437946T3 (da) | 2001-10-25 | 2012-07-23 | Miret Lab | Anvendelse af et kationisk konserveringsmiddel i fødevareprodukter |
PT1470234E (pt) | 2002-02-01 | 2008-11-10 | Miret Lab | Síntese enzimática de ésteres de n (alfa)-acil-l-arginina |
ES2292757T3 (es) | 2002-05-08 | 2008-03-16 | Laboratorios Miret, S.A. | Nuevos conservantes y sistemas protectores. |
JP4730760B2 (ja) * | 2004-05-25 | 2011-07-20 | 住友重機械工業株式会社 | Ri標識化合物合成システム |
US7731940B2 (en) | 2006-01-25 | 2010-06-08 | The Regents Of The University Of California | Compositions and methods related to serotonin 5-HT1A receptors |
US20130064770A1 (en) | 2010-05-28 | 2013-03-14 | Ge Healthcare Limited | Radiolabeled compounds and methods thereof |
GB201112987D0 (en) | 2011-07-28 | 2011-09-14 | Ge Healthcare Ltd | Novel compound |
GB201116359D0 (en) * | 2011-09-22 | 2011-11-02 | Ge Healthcare Ltd | Novel synthesis method |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0395313A2 (fr) * | 1989-04-22 | 1990-10-31 | American Home Products Corporation | Dérivés de pipérazine avec une fonction alkyle tertiaire |
EP0481744A1 (fr) * | 1990-10-19 | 1992-04-22 | JOHN WYETH & BROTHER LIMITED | Dérivés de pipérazine |
EP0512755A2 (fr) * | 1991-05-02 | 1992-11-11 | JOHN WYETH & BROTHER LIMITED | Dérivés de pipérazine |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0173310B1 (ko) * | 1989-04-22 | 1999-02-01 | 폴 에이 리쳐 | 피페라진 유도체 |
US4994258A (en) * | 1990-03-05 | 1991-02-19 | Merck & Co., Inc. | Gamma emitting, CCK-A antagonists for pancreatic imaging |
-
1993
- 1993-02-26 GB GB939303968A patent/GB9303968D0/en active Pending
-
1994
- 1994-02-17 DK DK94906348T patent/DK0686047T3/da active
- 1994-02-17 DE DE69422611T patent/DE69422611T2/de not_active Expired - Lifetime
- 1994-02-17 AT AT94906348T patent/ATE188614T1/de active
- 1994-02-17 WO PCT/GB1994/000324 patent/WO1994019026A1/fr active IP Right Grant
- 1994-02-17 AU AU60096/94A patent/AU6009694A/en not_active Abandoned
- 1994-02-17 PT PT94906348T patent/PT686047E/pt unknown
- 1994-02-17 ES ES94906348T patent/ES2141819T3/es not_active Expired - Lifetime
- 1994-02-17 EP EP94906348A patent/EP0686047B1/fr not_active Expired - Lifetime
- 1994-02-24 MX MX9401415A patent/MX9401415A/es unknown
-
1997
- 1997-08-18 US US08/914,131 patent/US6056942A/en not_active Expired - Lifetime
-
2000
- 2000-01-26 GR GR20000400174T patent/GR3032479T3/el unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0395313A2 (fr) * | 1989-04-22 | 1990-10-31 | American Home Products Corporation | Dérivés de pipérazine avec une fonction alkyle tertiaire |
EP0481744A1 (fr) * | 1990-10-19 | 1992-04-22 | JOHN WYETH & BROTHER LIMITED | Dérivés de pipérazine |
EP0512755A2 (fr) * | 1991-05-02 | 1992-11-11 | JOHN WYETH & BROTHER LIMITED | Dérivés de pipérazine |
Non-Patent Citations (4)
Title |
---|
CROUZEL ET AL., NUCL.MED.BIOL., vol. 19, no. 8, pages 857 - 870 * |
MATHIS ET AL., LIFE SCIENCES, vol. 55, no. 20, pages 403 - 407 * |
PIKE ET AL, MED. CHEM. RES., vol. 5, pages 208 - 227 * |
PIKE, J.PSYCHOPHARM., vol. 7, no. 2, pages 139 - 158 * |
Also Published As
Publication number | Publication date |
---|---|
ATE188614T1 (de) | 2000-01-15 |
DK0686047T3 (da) | 2000-04-25 |
DE69422611T2 (de) | 2008-10-09 |
PT686047E (pt) | 2000-06-30 |
GR3032479T3 (en) | 2000-05-31 |
ES2141819T3 (es) | 2000-04-01 |
AU6009694A (en) | 1994-09-14 |
WO1994019026A1 (fr) | 1994-09-01 |
GB9303968D0 (en) | 1993-04-14 |
DE69422611D1 (de) | 2000-02-17 |
EP0686047A1 (fr) | 1995-12-13 |
US6056942A (en) | 2000-05-02 |
MX9401415A (es) | 1994-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5609849A (en) | Serotonin (5-HT1A) receptor ligands and imaging agents | |
EP0686047B1 (fr) | Ligands de 5-ht 1a | |
Peroutka et al. | [3H] Mianserin: differential labeling of serotonin and histamine receptors in rat brain. | |
Farde et al. | Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects | |
Volkow et al. | PET evaluation of the dopamine system of the human brain | |
Wong et al. | Localization of serotonin 5‐HT2 receptors in living human brain by positron emission tomography using N1‐([11C]‐methyl)‐2‐BR‐LSD | |
Volkow et al. | Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain | |
US8119642B2 (en) | Structurally rigid dopamine D3 receptor selective ligands and process for making them | |
EP1119356B1 (fr) | Antagonistes radiomarques du recepteur de la neurokinine 1 | |
WO2005048810A2 (fr) | Traceurs radioactifs de recepteur sigma 2 permettant de mettre en image l'etat de proliferation de tumeurs solides | |
Shiue et al. | N-(N-benzylpiperidin-4-yl)-2-[18F] fluorobenzamide: a potential ligand for PET imaging of σ receptors | |
Udo de Haes et al. | Effect of fenfluramine‐induced increases in serotonin release on [18F] MPPF binding: A continuous infusion PET study in conscious monkeys | |
Broderick et al. | Cocaine acts on accumbens monoamines and locomotor behavior via a 5-HT2A/2C receptor mechanism as shown by ketanserin: 24-h follow-up studies | |
Kung et al. | In vivo SPECT imaging of 5‐HT1A receptors with [123I] p‐MPPI in nonhuman primates | |
AU780725B2 (en) | Spect imaging agents for serotonin transporters | |
US6251363B1 (en) | Diagnostic and therapeutic alkylenediamine compounds and process | |
Cliffe et al. | 5-HT 1A ligands | |
US8114379B2 (en) | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process | |
Lohith et al. | Evaluation in monkey of two candidate PET radioligands,[11C] RX‐1 and [18F] RX‐2, for imaging brain 5‐HT4 receptors | |
JP2010529124A (ja) | 新規方法 | |
Syvänen et al. | Synthesis of two potential NK 1-receptor ligands using [1-11 C] ethyl iodide and [1-11 C] propyl iodide and initial PET-imaging | |
EP1545525B1 (fr) | Antagonistes radiomarques du recepteur de la neurokinine-1 | |
Pike et al. | Preclinical development of a radioligand for the study of central 5-HT1A receptors with PET—[11C] WAY-100635 | |
CA2335493A1 (fr) | Nouveaux composes utiles dans le soulagement de la douleur |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19950727 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
17Q | First examination report despatched |
Effective date: 19960216 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 6A 61K 51/04 A |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
ITF | It: translation for a ep patent filed | ||
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
REF | Corresponds to: |
Ref document number: 188614 Country of ref document: AT Date of ref document: 20000115 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: E. BLUM & CO. PATENTANWAELTE Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 69422611 Country of ref document: DE Date of ref document: 20000217 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2141819 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20000315 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: JOHN WYETH & BROTHER LIMITED Free format text: JOHN WYETH & BROTHER LIMITED#HUNTERCOMBE LANE SOUTH TAPLOW#MAIDENHEAD BERKSHIRE, SL6 0PH (GB) -TRANSFER TO- JOHN WYETH & BROTHER LIMITED#HUNTERCOMBE LANE SOUTH TAPLOW#MAIDENHEAD BERKSHIRE, SL6 0PH (GB) |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20120227 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20120127 Year of fee payment: 19 Ref country code: CH Payment date: 20120126 Year of fee payment: 19 Ref country code: FR Payment date: 20120203 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20120127 Year of fee payment: 19 Ref country code: DE Payment date: 20120229 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20120222 Year of fee payment: 19 Ref country code: DK Payment date: 20120126 Year of fee payment: 19 Ref country code: BE Payment date: 20120312 Year of fee payment: 19 Ref country code: GB Payment date: 20120127 Year of fee payment: 19 Ref country code: GR Payment date: 20120130 Year of fee payment: 19 Ref country code: SE Payment date: 20120207 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20120215 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20120126 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20120223 Year of fee payment: 19 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20130819 |
|
BERE | Be: lapsed |
Owner name: *JOHN WYETH & BROTHER LTD Effective date: 20130228 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V1 Effective date: 20130901 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 188614 Country of ref document: AT Kind code of ref document: T Effective date: 20130228 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: ML Ref document number: 20000400174 Country of ref document: GR Effective date: 20130904 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20130217 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130228 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130228 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130901 Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130819 Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130218 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130904 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130228 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20131031 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 69422611 Country of ref document: DE Effective date: 20130903 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130217 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130217 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130228 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130228 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130217 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130228 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130903 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: MAXIMUM VALIDITY LIMIT REACHED Effective date: 20140217 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20140408 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20140225 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130217 Ref country code: PT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20130827 |